The Proteomics Core Facility makes advanced mass spectrometry instruments, expertise, and methods for protein analysis available to the Case Comprehensive Cancer Center (Case CCC) community. The core includes two laboratory sites, one on the Case campus and one the CCF campus, with a current total of 6000 sq. ft. of lab space. The core is directed by Dr. Mark Chance and has a total staff of approximately 20 individuals including scientists specializing in mass spectrometry, protein chemistry, instrument engineering, and bioinformatics. A total of 11 mass spectrometry systems are housed in the laboratories, including both electrospray and Maldi, and ion trap, ToF, QTof, and FTMS systems. The core was established in 1999, became a part of the Case CCC in 2003, and was expanded to its current form in 2005. The services that are offered to the Case CCC community are wide-ranging and range from a drop-off service for protein identification, to collaborative services for the detection and characterization of post-translation modifications, quantitative proteomics, and protein structural analyses to open instrument access for trained users. As a part of the Case CCC, the Proteomics Core has served a growing list of investigators. In 2005, approximately 100 investigators used the facilities, with about 40% being Case CCC members. Greater than 60% of the use was funded by the NIH. The Case CCC users come from 7 of the 9 scientific programs. All Case CCC members receive a 30% discount on the cost of services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-19
Application #
7599141
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
19
Fiscal Year
2008
Total Cost
$198,787
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101

Showing the most recent 10 out of 1227 publications